Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose open-label mass balance and metabolite study of oral [14C]-olorofim in healthy male volunteers
NL-OMON48360Active, not recruiting
- Sponsor
- F2G
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of olorofim in mycoses (3 cohorts), sponsored by F2G. Primary endpoints: Mass balance recovery and Metabolite profiling and identification sample collection. Started Aug 2019; status: active, not recruiting.
02
Drugs
olorofim
03
Conditions
mycoses
Beyond the preview
Go deeper on NL-OMON48360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48360.